EA201700426A2 - METHOD OF UNDERGROUND - Google Patents

METHOD OF UNDERGROUND

Info

Publication number
EA201700426A2
EA201700426A2 EA201700426A EA201700426A EA201700426A2 EA 201700426 A2 EA201700426 A2 EA 201700426A2 EA 201700426 A EA201700426 A EA 201700426A EA 201700426 A EA201700426 A EA 201700426A EA 201700426 A2 EA201700426 A2 EA 201700426A2
Authority
EA
Eurasian Patent Office
Prior art keywords
dione
amino
sodium salt
dihydroftalazin
substance
Prior art date
Application number
EA201700426A
Other languages
Russian (ru)
Other versions
EA201700426A3 (en
EA035278B1 (en
Inventor
Муса Тажудинович Абидов
Адмир Мусаевич АБИДОВ
Дмитрий Анатольевич МАЛЬЧУК
Александр Владимирович КУЛЕССКИЙ
Original Assignee
Общество с ограниченной ответственностью "АБИДАФАРМА"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "АБИДАФАРМА" filed Critical Общество с ограниченной ответственностью "АБИДАФАРМА"
Publication of EA201700426A2 publication Critical patent/EA201700426A2/en
Publication of EA201700426A3 publication Critical patent/EA201700426A3/en
Publication of EA035278B1 publication Critical patent/EA035278B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к медицине, а именно к лекарственным средствам, воздействующим на иммунную систему и обладающим иммуномодулирующим, противовоспалительным, противоопухолевым и антиоксидантным действием, а также к химико-фармацевтическому производству этих лекарственных средств. Способ получения стерильного лиофилизированного лекарственного препарата на основе натриевой соли 5-амино-2,3-дигидрофталазин-1,4-диона путем переработки безводной и/или двухводной нестерильной субстанции натриевой соли 5-амино-2,3-дигидрофталазин-1,4-диона отличается тем, что реализуют процесс переработки промежуточного продукта 5-амино-2,3-дигидрофталазин-1,4-диона в его натриевую соль путем растворения в водно-органическом щелочном растворе, так что безводную и/или двухводную субстанцию натриевой соли 5-амино-2,3-дигидрофталазин-1,4-диона получают кристаллизацией при температуре минус 5-7°С из водно-органического раствора натриевой соли 5-амино-2,3-дигидрофталазин-1,4-диона, после чего из субстанции получают стерильный лиофилизированный лекарственный препарат.The invention relates to medicine, namely to drugs that affect the immune system and possess immunomodulatory, anti-inflammatory, antitumor and antioxidant effects, as well as to the chemical and pharmaceutical production of these medicines. The method of obtaining a sterile lyophilized drug based on the sodium salt of 5-amino-2,3-dihydroftalazin-1,4-dione by processing the anhydrous and / or two-water unsterile substance of the sodium salt of 5-amino-2,3-dihydroftalazin-1,4- Dione differs in that they implement the processing of the intermediate product 5-amino-2,3-dihydroftalazin-1,4-dione into its sodium salt by dissolving in an aqueous-organic alkaline solution, so that the anhydrous and / or two-aqueous substance sodium salt 5- amino-2,3-dihydroftalazin-1,4-dione floor they are considered by crystallization at a temperature of minus 5-7 ° C from a water-organic solution of the sodium salt of 5-amino-2,3-dihydrophthalazine-1,4-dione, after which a sterile, lyophilized drug is obtained from the substance.

EA201700426A 2016-09-22 2017-09-21 Method of producing a sterile lyophilised medicinal preparation "tamerit" and/or "galavit" based on 5-amino-2,3-dihydrophthalazine-1,4-dione anhydrous sodium salt (tamerit) and/or based on 5-amino-2,3-dihydrophthalazine-1,4-dione dihydrous sodium salt (galavit) EA035278B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2016137827A RU2625267C1 (en) 2016-09-22 2016-09-22 Method for manufacture of non-sterile substances of non-aqueous "tamerit" and/or double-aqueous "galavit" - sodium salts of 5-amino-2,3-dihydrophthalazine-1,4-dione (versions) and methods for further processing thereof to obtain sterile medicinal preparations

Publications (3)

Publication Number Publication Date
EA201700426A2 true EA201700426A2 (en) 2018-03-30
EA201700426A3 EA201700426A3 (en) 2018-05-31
EA035278B1 EA035278B1 (en) 2020-05-22

Family

ID=59495465

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201700426A EA035278B1 (en) 2016-09-22 2017-09-21 Method of producing a sterile lyophilised medicinal preparation "tamerit" and/or "galavit" based on 5-amino-2,3-dihydrophthalazine-1,4-dione anhydrous sodium salt (tamerit) and/or based on 5-amino-2,3-dihydrophthalazine-1,4-dione dihydrous sodium salt (galavit)

Country Status (4)

Country Link
CN (1) CN109789139B (en)
EA (1) EA035278B1 (en)
RU (1) RU2625267C1 (en)
WO (1) WO2018056868A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2673452C1 (en) * 2017-08-15 2018-11-27 Межрегиональное общественное учреждение "Институт инженерной физики" Method of obtaining active pharmaceutical substance, presenting aminodihydrophthalazinedione of sodium
RU2744858C1 (en) * 2020-04-28 2021-03-16 Межрегиональное общественное учреждение "Институт инженерной физики" Method of obtaining lyophilisate of sodium aminodihydrophthalazinedione, or tameron medication
RU2760262C1 (en) * 2020-08-19 2021-11-23 Акционерное общество "Столетика" Suppositories with sodium aminodihydrophthalazinedione

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2113222C1 (en) * 1997-09-30 1998-06-20 Закрытое акционерное общество "Центр современной медицины "Медикор" Immunomodulating agent
WO2001072305A1 (en) * 2000-03-28 2001-10-04 Ramazanov, Ziadin Magomedovich A medicament and method for the production thereof
RU2211036C2 (en) * 2001-11-20 2003-08-27 Общество с ограниченной ответственностью "Абидофарма" Medicinal preparation (variants) and method for its production
RU2222327C2 (en) * 2002-03-22 2004-01-27 Общество с ограниченной ответственностью "Абидофарма" Method for preparing medicinal preparation
RU2302863C2 (en) * 2003-04-18 2007-07-20 Общество с ограниченной ответственностью "Абидофарма" Medicinal preparation (variants)
PL231885B1 (en) * 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia New method of manufacturing the 5-amino-2,3-dihydrophtalazine-1,4-dione salts with alkali metals and their application in medicine
CN102971300B (en) * 2010-03-01 2016-03-02 梅特里奥药品股份公司 The crystal formation of amino-2,3-dihydros-(2，3-benzodiazine)-Isosorbide-5-Nitrae-dione sodium salt of 5-, containing their pharmaceutical preparation and the production method of described crystal formation
RU2439063C1 (en) * 2010-06-30 2012-01-10 Общество с ограниченной ответственностью "Поливит" Method of obtaining medication
RU2454221C2 (en) * 2010-07-06 2012-06-27 Общество с ограниченной ответственностью "Завод Медсинтез" Method for preparing lyophilised antiviral agent
WO2016096143A1 (en) * 2014-12-18 2016-06-23 Metriopharm Ag Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form

Also Published As

Publication number Publication date
EA201700426A3 (en) 2018-05-31
EA035278B1 (en) 2020-05-22
CN109789139A (en) 2019-05-21
CN109789139B (en) 2021-05-18
RU2625267C1 (en) 2017-07-12
WO2018056868A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
EA201991693A1 (en) PYRIDINE DERIVATIVE AS ASK1 INHIBITOR AND METHOD FOR PRODUCING AND USE
EA201700426A3 (en) METHOD OF UNDERGROUND
NZ631100A (en) Soft chewable pharmaceutical products
EA202090573A1 (en) COMPOSITIONS OF NIRAPARIBA
EA201590797A1 (en) PREPARATIONS WITH THE MODIFIED PROBE RELEASE
EA201700019A1 (en) HIGHLY PURE ORIENTATION AND METHOD FOR ITS OBTAINING
RU2018126158A (en) APPLICATION OF TRIACETHYL-3-HYDROXYPHENYLENADENOSINE FOR THE PRODUCTION OF A PHARMACEUTICAL MEDICINE FOR THE PREVENTION OR TREATMENT OF A NON-ALCOHOLIC LIVER LIVER DISEASE DISEASE
EA201890575A1 (en) COMPOSITIONS AND METHODS FOR THE SENSITIZATION OF PARASITES TO MEDICINES
EA201791995A1 (en) MEANS FOR THE TREATMENT OF RESPIRATORY INFECTION
EA201790140A1 (en) PHARMACEUTICAL MEDICINE FORMS
EA201792513A1 (en) Heteroaryl carbonitriles for the treatment of disease
Mahmoudi et al. What could have caused this weight loss?
TH1701001398A (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-il compounds And using it as a SGRM controller
TH167583A (en) Carboxamide derivatives
TH167687A (en) Medicine to prevent or treat constipation
UA114828C2 (en) APPLICATION OF DECAMETOXIN AS A PHARMACEUTICAL ACTIVE SUBSTANCE FOR TREATMENT OF Gastrointestinal and Intestinal Infections Oral
EA201892350A1 (en) PREPARATION FOR INHALATION ON THE BASIS OF ISOGLYCYRRISINIC ACID OR ITS SALT AND ITS APPLICATION IN THE OBTAINING OF MEDICINES FOR TREATING DISEASES OF THE RESPIRATORY SYSTEM
TH168837A (en) Derivative of 4- alkyline imidazole and pharmaceutical products that contain it As an active ingredient
TH1801001578A (en) One or two-site substituted indole derivatives that inhibit dengue virus proliferation.
TH182770A (en) Aldosteron Synthes inhibitors
TH167540A (en) Tylosin derivatives (TYLOSIN) and methods for their preparation
TH163311A (en) Organic compound formula
Radzinskaya et al. Infectious endocarditis in patients with injection drug use
TH173708A (en) The process for obtaining an active, active perlindoanthiomer. Optical and salt of these
TH1701006461A (en) An amino-hydrothiazine derivative fused by tetrahydrofurane, useful in the treatment of Alzheimer's disease.